LED Medical Diagnostics Inc.

LED Medical Diagnostics Inc.

March 13, 2012 14:07 ET

VELscope Vx® Approved for Use by AppleWhite Dental Partners

Handheld device is world's leading system for early detection of oral cancer and other oral disease

BURNABY, BRITISH COLUMBIA--(Marketwire - March 13, 2012) - LED Medical Diagnostics Inc. (TSX VENTURE:LMD) announced today that its VELscope Vx enhanced early detection system has just been approved for use by AppleWhite Dental Partners. The VELscope Vx is exclusively distributed in the U.S. and Canada by Henry Schein, Inc. (NASDAQ:HSIC).

"We are very pleased that the VELscope Vx has received the approval of yet another demanding and respected group dental practice," said Peter Whitehead, founder and CEO of LED Dental and its parent company, LED Medical Diagnostics Inc. (TSX VENTURE:LMD). "AppleWhite Dental Partners takes great pains to select only the finest technologies for its practices and their patients, and it is very gratifying to have them approve our VELscope Vx."

LED Dental introduced the first generation of VELscope's fluorescence visualization technology about five years ago in response to the fact that oral cancer was one of the few types of cancer that had not experienced a significant decline in mortality over the previous several decades. VELscope technology gives dental practitioners an adjunctive visualization aid that should be used together with, and after, a traditional intra-and extra-oral head and neck exam in hopes of detecting oral lesions that might otherwise have been overlooked.

"Our mission is to create a partnership with our dentists that allow them to practice innovative dentistry and provide an outstanding patient experience," said Dr. Thomas McCoy, CEO of AppleWhite Dental Partners. "Adding the state-of-the-art VELscope Vx enhances the ability of our dentists to discover oral cancer and other oral disease in early stages, and in a way that is completely non-invasive for their patients."

The National Cancer Institute's SEER website indicates that oral cancer is most often detected in late stages, when the 5-year survival rate is less than 50%. When detected early, however, the 5-year survival rate leaps to approximately 82%. Because the VELscope Vx is so sensitive to oral mucosal changes, it can help increase the odds that cancer will be detected in early and even precancerous stages.

"In fact," said Mr. Whitehead, "VELscope technology increases the likelihood of detecting all types of oral disease at earlier stages, which is good news for the patient as well as the practice."

Since the launch of the first generation model, over 10,000 VELscope devices have been purchased by dental practices globally. It is estimated that these devices have been used to conduct over 10 million oral cancer exams during that time, easily making the VELscope the world's number one adjunctive oral cancer screening technology.

The VELscope Vx, the latest generation of the technology, is the first to offer cordless convenience as well as an optional digital camera and customized bracket that make it easy for dentists to photo-document suspicious lesions that are referred to specialists for surgical biopsy.

"We have considered all available options," said Dr. Mark Mosier, Director of Dentistry for AppleWhite Dental Partners, "and we are confident that the VELscope Vx offers the most effective, most convenient and most economical solution for both our practices and their patients."

AppleWhite Dental Partners provides an array of services to 17 participating dental practices in Iowa, Illinois and Minnesota. By providing business support, professional mentoring, and administrative and consulting services, AppleWhite Dental Partners allows its participating dentists to devote their time to caring for patients, continuing education, and honing clinical skill.

About LED Medical Diagnostics Inc.

Founded in 2003, LED Medical Diagnostics Inc., (TSX VENTURE:LMD) is a fast-growing public company offering effective early-stage oral cancer detection technologies in 23 countries worldwide. The company makes the VELscope Vx, a powerful tool for detecting early stage oral cancer that is approved by the FDA, Health Canada and European regulators. The company is headquartered in Burnaby British Columbia, Canada. For more information please call +1 (604) 434-4614, or visit www.VELscope.com.

About the VELscope Vx

The VELscope Vx is a powerful FDA-approved tool used to screen for oral cancer. It saves lives by helping detect early stage oral cancer and pre-cancer and other abnormalities in the mouth such as viral, fungal and bacterial infections. The VELscope Vx is exclusively distributed worldwide through a partnership with Henry Schein, the world's largest dental distribution company. For more information please call +1 (604) 434-4614, or visit www.VELscope.com.

Contact Information